Author

Michael P. Collins

Foghorn Therapeutics (United States)ORCID 0000-0002-1806-6775Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

Anna MalovannayaiD· 1 shared Antrix JainiD· 1 shared Branko CuglievaniD· 1 shared Christine E. Birdwell· 1 shared Christopher Peter MilliD· 1 shared Courtney Denton DinardoiD· 1 shared Danielle E. HammondiD· 1 shared Hanxi HouiD· 1 shared

Activity by Year

2024-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Anna MalovannayaORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Cancer BiologyBloodPeer-reviewedMar 4, 2024

BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor

Warren C. Fiskus, Jessica C. Piel, Michael P. Collins…·Kapil N. Bhalla

This study shows that FHD-286, a BRG1/BRM inhibitor, reduces AML burden and improves survival when combined with Menin or BET inhibitors in xenograft models of AML with MLL1r or mtNPM1.

49 citationstop 2%

humanbulk RNA-seq

𝕏 PostBluesky